• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lawrence F. Eichenfield Describes the Differences Between Treating Adult vs Pediatric Patients With AD

Video

Pediatric patients with atopic dermatitis (AD) often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, said Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

Pediatric patients with atopic dermatitis often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, according to Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and vice-chair and professor of dermatology and pediatrics at UC San Diego School of Medicine.

Transcript

How does treating pediatric patients with atopic dermatitis differ from treating adult patients?

Eichenfield: In any patient with atopic dermatitis, we're assessing the severity of the disease and also the course of the disease, the persistence. In pediatric atopic dermatitis, we have this tremendous variation, from young infants who might have disease that's easy to get under control, with traditional mild topical corticosteroids and they just need moisturizers in between, to more severe diseases. But as we go on in an age to the older children and teens, there's always issues in terms of what's an appropriate amount of topical therapy to control disease and keep it under control. It's a lot of work, with different topical agents. We have both our steroids and nonsteroids. We have to work with the families to understand what's a safe amount of medicine to use and to determine if we need something beyond topical medicines to keep the disease under control.

Related Videos
Bhavana (Tina) Bhatnagar, DO, West Virginia University Cancer Institute at Wheeling Hospital
Dr Marco del Riccio
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Michael David Chuong, MD, radiation oncologist, Miami Cancer Institute, Baptist Health South Florida
Yuman Fong, MD, cancer surgeon, City of Hope
Dr Marco del Riccio
Elena Elimova, MD, associate professor in the Department of Medicine at the University of Toronto and staff medical oncologist at Princess Margaret Hospital
Dr Eric Yang
Adam Brufsky, MD, PhD, University of Pittsburgh
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, assistant professor in the department of integrative translational sciences at City of Hope
© 2026 MJH Life Sciences
AJMC®
All rights reserved.